Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA blesses Merck's grass pollen allergy drug

This article was originally published in Scrip

Executive Summary

Merck won approval from the FDA on 14 April to market its allergy sublingual immunotherapy tablet Grastek against Phleum pratense, or Timothy grass pollen – one of the most common grasses in the US, which has been demonstrated to be cross-reactive with other grasses, including sweet vernal, orchard, perennial rye, Kentucky blue, meadow fescue and redtop.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel